Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis

  • Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol. 2017;4:e202–e17.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11:543–52.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rasche M, Zimmermann M, Borschel L, Bourquin JP, Dworzak M, Klingebiel T, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 2018;32:2167–77.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Creutzig U, Zimmermann M, Dworzak MN, Gibson B, Tamminga R, Abrahamsson J, et al. The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. Haematologica 2014;99:1472–8.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet 2018;392:593–606.

    PubMed 

    Google Scholar 

  • Moors I, Vandepoele K, Philippe J, Deeren D, Selleslag D, Breems D, et al. Clinical implications of measurable residual disease in AML: Review of current evidence. Crit Rev Oncol Hematol. 2019;133:142–8.

    PubMed 

    Google Scholar 

  • Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10:506–25.

    CAS 
    PubMed 

    Google Scholar 

  • Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol 2020;21:551–60.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, et al. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Munster study group. Haematologica 2019;104:120–7.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, et al. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. Haematologica 2018;103:1484–92.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl J Med. 2019;380:1726–37.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell Lymphoma. N. Engl J Med. 2019;380:45–56.

    CAS 
    PubMed 

    Google Scholar 

  • Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med 2019;25:947–53.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10:53.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N. Engl J Med. 2018;378:439–48.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl J Med. 2018;378:449–59.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372–85.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007;110:2659–66.

    PubMed 

    Google Scholar 

  • Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, et al. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood 2017;129:609–18.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jiang YP, Liu BY, Zheng Q, Panuganti S, Chen R, Zhu J, et al. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018;2:1738–49.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, et al. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine 2019;20:102004.

    CAS 
    PubMed 

    Google Scholar 

  • Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, et al. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type Lectin-like Molecule 1. Mol Ther. 2017;25:2202–13.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11:7.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhang H, Wang P, Li Z, He Y, Gan W, Jiang H. Anti-CLL1 chimeric antigen receptor T-Cell therapy in children with relapsed/refractory acute myeloid leukemia. Clin Cancer Res. 2021;27:3549–55.

    CAS 
    PubMed 

    Google Scholar 

  • Liu F, Cao Y, Pinz KG, Ma Y, Wada M, Chen KH, et al. First-in-Human CLL1-CD33 Compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on Phase 1 clinical trial. Am Soc Hematol Annu Meet: Blood. 2018;132:901.

    Google Scholar 

  • Zhang H, Gan WT, Hao WG, Wang PF, Li ZY, Chang LJ. Successful Anti-CLL1 CAR T-cell therapy in secondary acute myeloid leukemia. Front Oncol. 2020;10:685.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424–47.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019;16:45–63.

    CAS 
    PubMed 

    Google Scholar 

  • Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.

    CAS 
    PubMed 

    Google Scholar 

  • Hofmann S, Schubert ML, Wang L, He B, Neuber B, Dreger P, et al. Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). J Clin Med. 2019;8:200.

    CAS 
    PubMed Central 

    Google Scholar 

  • Mardiana S, Gill S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020;10:697.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugue S, et al. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. Haematologica 2018;103:e424–e6.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Budde L, Song JY, Kim Y, Blanchard S, Wagner J, Stein AS, et al. Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Am Soc Hematol Annu Meet: Blood. 2017;130:811.

    Google Scholar 

  • Liu F, Zhang H, Sun L, Li Y, Zhang S, He G, et al. First-in-human CLL1-CD33 compound CAR (cCAR) T cell therapy in relapsed and refractory acute myeloid leukemia. European Hematology Association Meeting; 06/12/202020. S149.

  • Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain 2019;142:1334–48.

    PubMed 

    Google Scholar 

  • Belin C, Devic P, Ayrignac X, Dos Santos A, Paix A, Sirven-Villaros L, et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep. 2020;10:18997.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Petrov JC, Wada M, Pinz KG, Yan LE, Chen KH, Shuai X, et al. Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia 2018;32:1317–26.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Ma H, Padmanabhan IS, Parmar S, Gong Y. Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol. 2019;12:41.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang J, Hu Y, Huang H. Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy. J Leukoc Biol. 2017;102:1347–56.

    CAS 
    PubMed 

    Google Scholar 

  • Zhang LN, Song Y, Liu D. CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. J Hematol Oncol. 2018;11:41.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia 2017;31:2587–93.

    CAS 
    PubMed 

    Google Scholar 

  • Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 2019;133:1652–63.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ma Y, Zhang S, Fang H, Yu K, Jiang S. A phase I study of CAR-T bridging HSCT in patients with acute CD19(+) relapse/refractory B-cell leukemia. Oncol Lett. 2020;20:20.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15:88.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Source

    Similar Posts